The Regeneration Revolution "Stem Cells and the Quest to Cure Diabetes"

- **Sanjay Dhar**, MS, MPhil, PhD

Director of Stem Cell Program & Research

Hoskinson Health and Wellness Clinic

Gillette, WY 82718

1

The Burden of Diabetes (2026 Update)

Global Pandemic: Over 540 million people living with diabetes worldwide.

U.S. Impact: ~40.1 million Americans (1 in 8) have diabetes; 115 million have prediabetes.

Economic Strain: Costs exceeded $640 billion in recent years, accounting for 25% of all U.S. healthcare spending.

The "Hidden" Burden: 1 in 4 adults with diabetes are undiagnosed; high risk of microvascular (kidney, eye) and macrovascular (heart) complications.

2

Pathophysiology Relevant to Stem Cells

Type 1 (T1D): Autoimmune destruction of β-cells to Absolute insulin deficiency.

Type 2 (T2D): Insulin resistance + Progressive β-cell exhaustion/failure.

The Regenerative Gap: Endogenous β-cell regeneration is insufficient to keep up with metabolic demand or autoimmune attack.

Target: Stem cells aim to either replace the lost mass or repair the environment.

3

Why Stem Cells for Diabetes?

Beyond Insulin: Insulin is a "bandage," not a cure. It doesn't prevent glycemic variability or long-term complications.

Limitations of Cadaveric Islets: Extreme donor shortage; only ~25% of recipients remain insulin-independent after 5 years.

Scalability: Stem cells (hESCs/iPSCs) provide an "infinite" source of β-cells.

Disease Modification: Mesenchymal Stem Cells (MSCs) can potentially halt the disease process via immunomodulation.

4

Replacement (Pluripotent Stem Cells): Creating new β-cells from Embryonic (hESCs) or Induced Pluripotent (iPSCs) cells.

Support (MSCs): Using Mesenchymal Stem Cells for their anti-inflammatory "secretome."

Encapsulation/Bioengineering: Placing cells in "pouches" to protect them from the immune system without needing lifelong drugs.

Major Stem Cell Strategies

5

"iPSCs vs MSCs"

A Comparison

Feature	iPSCs (Induced Pluripotent)	MSCs (Mesenchymal)
Origin	Reprogrammed adult cells (skin/blood)	Bone marrow, fat, umbilical cord
Primary Goal	**Replacement** of β-cells	**Modulation** (immune system), **Replacement** (β-cells)
Potency	Pluripotent (can become most cell types)	Multipotent (any types)
Immunogenicity	Can be autologous (low rejection)	Autologous & Allogenic "Immune privileged" (low rejection)
Risk	Higher risk of teratoma (tumor)	Lower risk; transient survival

6

Clinical Progress

"Stem Cell Derived Islets in T1D"

VERTEX VX-880/VX-264: LANDMARK TRIALS SHOWING PATIENTS ACHIEVING INSULIN INDEPENDENCE USING FULLY DIFFERENTIATED STEM CELL-DERIVED ISLETS.

SUCCESS METRICS: SUSTAINED HBA1C <7.0%, ELIMINATION OF SEVERE HYPOGLYCEMIC EVENTS, AND MEASURABLE C-PEPTIDE (PROOF OF INTERNAL INSULIN PRODUCTION).

THE GOAL: MOVING FROM SYSTEMIC IMMUNOSUPPRESSION TO "CLOAKED" OR GENE-EDITED CELLS THAT THE IMMUNE SYSTEM IGNORES.

7

Regulatory Milestone

"Lantidra"

Context: First-ever FDA-approved allogeneic pancreatic islet cellular therapy (2023/2024).

Indication: Adults with T1D who cannot reach target HbA1c due to repeated episodes of severe hypoglycemia despite intensive management.

Significance: It paved the regulatory pathway for "cell therapy as a drug," setting the stage for more advanced stem cell products in 2026.

8

MSC Therapy Rationale

THE "CELLULAR PHARMACY": MSC DON'T JUST REPLACE CELLS; THEY SENSE INFLAMMATION AND SECRETE "HEALING FACTORS."

PARACRINE SIGNALING: RELEASE OF TGF-B, IL-10, AND HGF TO DAMPEN T-CELL ATTACKS.

ANGIOGENESIS: PROMOTING BETTER BLOOD FLOW TO REMAINING PANCREATIC ISLETS.

9

MSCs in Type 1 vs. Type 2 Diabetes

- **In T1D**: Focus is on preservation. Administering MSCs early (Stage 3 T1D) to stop the immune system from killing the remaining 10–20% of β-cells.
- **In T2D**: Focus is on sensitivity and inflammation. MSCs help reduce systemic "meta inflammation" and improve how tissues respond to insulin.

10

How MSCs Work

"The Mechanism"

T-Reg Promotion: Increases "peacekeeper" T-cells.

Dendritic Cell Inhibition: Stops the "alarm" system of the immune response.

Anti-Apoptotic Effects: Directly protects β-cells from dying under stress.

11

Comparison:

β-cell Replacement vs. MSC Therapy

- **Replacement (β-cells)**: High impact, curative intent, requires protection from autoimmunity, technically complex.
- **Support (MSCs)**: Moderate impact, "disease-modifying" intent, simpler delivery (IV infusion), acts more as a "booster" for the body's own cells.

12

Safety Risks and Ethical Issues

Tumorigenicity: Risk of undifferentiated iPSCs forming teratomas.

Ethical Concerns: Historic use of embryonic cells (hESCs); iPSCs largely bypass this but raise "genetic editing" questions.

Immune Rejection: Even "immune privileged" cells may eventually be cleared by the host.

MSCs: Do not exhibit any of the above function.

13

Regulatory and Translational Landscape

- **Fast Track/RMAT**: FDA using "Regenerative Medicine Advanced Therapy" designations to speed up approvals.
- **Manufacturing**: The shift from "lab-bench" to "industrial-scale" bioreactors to treat millions rather than dozens.

14

Future Directions:

Wyoming "Stem Cell Freedom Act"



- **Recent Legislation (March 2026)**: Wyoming signed the "Stem Cell Freedom Act" (SF 48) into law.
- **Impact**: Authorizes physicians to perform non-FDA-approved stem cell therapies under strict IRB oversight and Good Manufacturing Practices (GMP).
- **Significance**: Represents a state-level push to increase patient access to "Right to Try" regenerative treatments, potentially creating a new model for domestic medical tourism in the U.S.

15

Take-Home Message

Diabetes is no longer just "managed"; we are learning to "reverse" it.

Pluripotent cells offer the hope of a functional cure for T1D via replacement.

MSCs provide a powerful tool for T2D and early T1D via immunomodulation.

2026 is a tipping point where regulatory frameworks (Lantidra, Wyoming Act) are finally catching up to the science.

16